Blog

On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use. The PA9159 developed by Zhejiang Palaatu Pharmaceutical Company (Palaatu) is for seasonal and perennial allergic rhinitis. Class 1 new drug PA9159 for rhinitis In addition, Palaatu plans to submit the clinicalRead more

Safety assessment lab of process chemistry In the research and development process of innovative drugs, the chemical process research of drugs plays a pivotal role.  During the synthesis process to the scale up process in the laboratory, it is not only about output, but also various errors and risks.  Therefore, in the development of innovativeRead more

Shanghai Medicilon Inc. recently assigned Dr. Haifeng Yin as the vice president of process chemistry and formulation study, Dr. Baohong Cao as the vice president of pharmacology. Dr. Chunlin Chen, the founder and CEO of Medicilon, welcomed the two and hoped that their participation will bring new innovation and development momentum to Medicilon, bringing aRead more

On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA).  HG381 for injection is a new Category I Chemical Drug and is clinically intended to be used for the treatment of advanced tumors. HG381 is new molecular entity developed by HitGen basedRead more

#Medicilon will exhibit the 2021 AACR Virtual Annual Meeting from April 10-15.  Please visit our virtual booth for more information on our oncology and preclinical services.  We look forward to see you. #Medicilon #Oncology #DrugDiscovery #AACR21Read more

Livzon Pharmaceutical Group Inc. (Livzon) obtained a “novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No. 2021L90001, 2021L90002, 2021L90003).  V-01 is to prevent diseases caused by novel coronavirus infection. V-01 is an innovative novel coronavirus recombinant protein vaccine developed by Livzon and the Institute of Biophysics,Read more

Medicilon will exhibit the 2021 SOT Virtual Annual Meeting from March 12-26.  Please visit our virtual booth to meet our VPs, Dr. Frank Wang, Dr. Mingzhu Zhang, Dr. Tao Ye and Sally Tang, for more information on our toxicology services.  We look forward to see you. #Medicilon #Toxicology #DrugDiscovery #SOT2021Read more

Thank you for your business, support and partnership in 2020!  Medicilon appreciates working with you and hope that the coming year will bring you happiness and success.Read more

Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines has the capacity to develop innovative drugs with global intellectual property rights, which has laid a solid foundation for the achievement of the company’s long-term sustainable development strategic goals. 3D011Read more

Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610 was the 14th innovative medicine that was approved of clinical trials. XZP is one small molecule agonist with high efficiency, high selectivity and novel structure that can significantly improve theRead more